Close
Aaron Pearson
Vice President of Public Relations

The need for widespread COVID-19 testing of millions of people has surfaced another shortage, nasal swabs. Stratasys has added to its efforts to fight the pandemic and ongoing testing requirements by marketing and promoting Origin 3D-printed nasopharyngeal (NP) swabs to healthcare providers and other testing centers in the U.S. The Origin 3D-printed nasopharyngeal swab has been tested in a clinical trial and is considered an FDA Class I Exempt Device.


The clinical trial was conducted by Beth Israel Deaconess Medical Center, an academic medical center affiliated with Harvard Medical School, and Origin reports their results performed highest with regard to concordance to control swabs compared to two other 3D printed swabs. In addition, in subjective feedback, Origin swabs were preferred over the other 3D printed swabs for comfort.



 Download clinical trial